Mohammed Alasmary

Dr. Mohammed Alasmary

Najran University, Najrān, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in International Journal of Polymeric Materials and Polymeric Biomaterials
Verified
Journal Article
Closed access
Mohammad Zaki AhmadMohammad Zaki Ahmad
Mohammad Zaki Ahmad
RIRizwanullah
Rizwanullah
Javed AhmadJaved Ahmad
Javed Ahmad
MAMohammed Alasmary
Mohammed Alasmary
MAMd Habban Akhter
Md Habban Akhter
Anzarul HaqueAnzarul Haque
Anzarul Haque
Cancer is among the most dreadful fatal diseases globally, and the efficacy of recent chemotherapeutic approaches is limited due to many related drawbacks. The major limitation associated with cancer chemotherapy is the poor aqueous solubility of most of the anticancer drugs, development of multidrug resistance, low bioavailability, small plasma half-life, and serious side effects to healthy tissues due to unspecific distribution of chemotherapeutic drugs. Advancement in nanoscience provides the means of specific and selective targeting of cancer cells. Chitosan, one of the naturally occurring biocompatible and mucoadhesive biopolymers that have been widely used in recent years for the effective delivery of anti-cancer drugs at the target site. Chitosan nanoparticles can encapsulate both hydrophilic and lipophilic chemotherapeutic drugs, proteins/peptides as well as different genetic materials like DNA, miRNA, siRNA, etc. in their polymeric matrix. Due to the unique polymeric matrix, these nanoparticles improve the solubility as well as the stability of encapsulated molecules in the biological system. Chitosan nanoparticles can improve the pharmacokinetic profile as well as the therapeutic efficacy of encapsulated drugs by controlling the release rates and targeted delivery process. These nanoparticles selectively deliver the encapsulated drugs to desired sites through passive or active targeting mechanisms thereby decrease the undesirable side-effects. The surface of chitosan nanoparticles can be modified with different ligands like antibodies, proteins, peptides, polysaccharides, and nucleic acids to achieve selective targeting. This review will provide a state-of-the-art perspective on recent development in chitosan-nanoparticles for smart anti-cancer therapeutic delivery. Graphical Abstract

1 November 2020 in Expert Review of Vaccines
Verified
Journal Article
Closed access
Mohammad Zaki AhmadMohammad Zaki Ahmad
Mohammad Zaki Ahmad
Javed AhmadJaved Ahmad
Javed Ahmad
Anzarul HaqueAnzarul Haque
Anzarul Haque
MAMohammed Alasmary
Mohammed Alasmary
Basel A Abdel-WahabBasel A Abdel-Wahab
Basel A Abdel-Wahab
SASohail Akhter
Sohail Akhter
Introduction: Cancer immunotherapy is a fast-growing field that has achieved tremendous progress in recent years. It is one of the most potent tools that can activate the immune system against cancer. Nevertheless, the development of safe and effective vaccines to overcome emerging new disease remains challenging since several emerging antigens are poorly immunogenic. Nanotechnology has provided a realistic resolution for the drawback of traditional cancer immunotherapy. Area covered: This review discusses different cancer immunotherapy approaches focusing on recent advancements in nanomedicine-based cancer immunotherapy. The literature review method includes inclusion and exclusion criteria to categorize important articles. The literature survey was carried out using PubMed, Google Scholar, Scopus, and the Saudi digital library. Expert opinion: In the last two decades, the development and application of nanoparticles incorporating antigen/adjuvant in cancer immunotherapy have experienced rapid growth. Soon, progressively multifaceted nanovaccines presenting different antigens and co-delivered with antigens will be clinically translated. Better understanding and improved knowledge of nanomedicines-based delivery approaches and immunostimulatory action, and in-vivo biodistribution would inevitably facilitate the altruistic design of cancer nanovaccine for humankind.

11 May 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
Mohammad Zaki AhmadMohammad Zaki Ahmad
Mohammad Zaki Ahmad
Javed AhmadJaved Ahmad
Javed Ahmad
MAMohammed Alasmary
Mohammed Alasmary
SASohail Akhter
Sohail Akhter
MAMohammed Aslam
Mohammed Aslam
MAM.M. Abdullah
M.M. Abdullah

18 March 2022 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
SASaif Aboud M. Alqahtani
Saif Aboud M. Alqahtani
ZAZuhier A. Awan
Zuhier A. Awan
MAMohammed Alasmary
Mohammed Alasmary
SASaeed M. Al Amoudi
Saeed M. Al Amoudi
Objective: This study aimed to decipher the association between serum uric acid (UA) and glycated hemoglobin (HbA1c) in the population from the southern region of Saudi Arabia. Method: In this retrospective cross-sectional investigation, clinical data obtained from the different commercial laboratories in the Asir region of Saudi Arabia were screened over 2 years. Data were analyzed using standard statistical methods. Results: A total of 1984 laboratory investigations with 1215 females (61.2%) and 769 males (38.6%) were included in the data analysis. In our investigation, the prevalence of hyperuricemia in the study population was 53.5% (41.2% females and 12.3% males) and in the diabetic population was 12.7% (9.47% females and 3.23% males), in prediabetics was 12.65% (9.8% females and 2.85% males), respectively. Prediabetic subjects had higher UA levels than people with diabetes or healthy people. Higher UA quartiles were associated with a high level of urea, blood urea nitrogen (BUN) creatinine, HbA1c, fasting blood sugar (FBS), and total cholesterol (TC) (P < 0.05). High UA (OR = 1.33 for diabetes; OR = 2.676 for prediabetes), high BUN (OR = 3.05 for diabetes; OR = 2.293 for prediabetes), high TC (OR = 3.75 for diabetes; OR = 1.098 for prediabetes), and high TG (OR = 2.67 for diabetes; OR = 1.943 for prediabetes) parameters are the most influential risk factor in diabetic and prediabetic patients than the people who have normal UA, BUN, TC, and TG value. Conclusion: High UA levels are significantly associated with prediabetes as defined by HbA1c criteria, indicating that UA has a significant role in the disturbance of glucose metabolism. A significant positive association was observed between dyslipidemia and serum UA in the study population.

25 February 2021 in Immunotherapy
Verified
Journal Article
Closed access
Mohammad Zaki AhmadMohammad Zaki Ahmad
Mohammad Zaki Ahmad
Javed AhmadJaved Ahmad
Javed Ahmad
MAMohammed Alasmary
Mohammed Alasmary
Basel A Abdel-WahabBasel A Abdel-Wahab
Basel A Abdel-Wahab
MWMusarrat Warsi
Musarrat Warsi
PCPramila Chaubey
Pramila Chaubey
Advancements in the field of cancer therapeutics have witnessed a recent surge in the use of liposomes. The physicochemical characteristics of the liposomes and their components, including the lipi...

25 March 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
BMBasheerahmed Abdulaziz Mannasaheb
Basheerahmed Abdulaziz Mannasaheb
SASarah Abdulrahman Alajlan
Sarah Abdulrahman Alajlan
JAJaber Abdullah Alshahrani
Jaber Abdullah Alshahrani
NONoordin Othman
Noordin Othman
SASultan Othman Alolayan
Sultan Othman Alolayan
MAMohammed Alasmary
Mohammed Alasmary
Irrational Self-Medication (SM) practice leads to incorrect diagnosis and is a risk factor for disease exacerbation and serious health consequences. Hence Responsible SM is vital for better health outcomes. In the present community-based study we explored the SM practice during the last 3 months, frequency, outcome, medications used, reasons influencing SM, source of the drug, and information. Data were analyzed using SPSS; chi-square test was performed to indicate significance, Odds ratio, Pearson correlation, univariant and multivariant regression analysis were performed to find out factors and predictors of SM. A total of 611 residents completed the survey. SM was practiced by 52.9% of participants during the last 3 months, with a frequency of one to two times. Headache (64.8%), pain (35.4%), fever/flu (31.4%), cold & cough (21.9%) and dysmenorrhea (20.9%) were illnesses managed using pain killers (75.9%), multivitamins (25.5%), anti-pyretic (24.7%) and herbal medicines (18.5%). Minor illness (67.9%), earlier experience (33.9%) and shortness of time to attend healthcare facilities (18.8%) were the reasons for practicing SM. Distance to healthcare and routine physical activity have significantly influenced the SM practice. Residents stated that inappropriate SM would lead to negative outcomes, including drug side effects (70%), Interaction (34.2%), poor treatment outcome (32.6%) and return of symptoms (26.5%). Interestingly, two-thirds of participants (68.9%) have recommended SM in case of minor illnesses only, 85.3% of respondents have expressed their desire to learn more about appropriate SM, and 76.6% are willing to return their leftover or unused medications to drug take-back centers.